Treatments for stage 2 esophageal cancer

The following are treatment options for stage 2 esophageal cancer. Your healthcare team will suggest treatments based on your needs and work with you to develop a treatment plan.

You may have a feeding tube put in, so that you can gain weight and maintain good nutrition during treatment.

Chemotherapy and chemoradiation

Chemotherapy is usually combined with radiation therapy to treat stage 2 esophageal cancer. This is called chemoradiation. The 2 treatments are given during the same time period.

Chemoradiation may be offered for stage 2 esophageal cancer:

  • before surgery (neoadjuvant therapy)
  • after surgery (adjuvant therapy), especially for esophageal adenocarcinoma tumours
  • as the main treatment for tumours that are found in the upper part of the esophagus that is in the neck

Chemotherapy by itself may be offered before surgery for stage 2 esophageal tumours at the gastroesophageal (GE) junction.

People with stage 2 esophageal cancer who aren't healthy enough to have surgery, or who don't want to have surgery, may be offered chemotherapy or chemoradiation as the main treatment.

The most common chemotherapy drugs used to treat stage 2 esophageal cancer are:

  • capecitabine (Xeloda)
  • cisplatin and capecitabine
  • cisplatin and etoposide (Vepesid)
  • cisplatin and fluorouracil
  • cisplatin and irinotecan
  • carboplatin and fluorouracil
  • carboplatin and irinotecan
  • carboplatin and paclitaxel
  • epirubicin, carboplatin and fluorouracil
  • epirubicin, carboplatin and capecitabine
  • epirubicin, cisplatin and capecitabine
  • epirubicin, cisplatin and fluorouracil
  • fluorouracil and leucovorin
  • docetaxel (Taxotere), oxaliplatin, fluorouracil and leucovorin
  • oxaliplatin, fluorouracil and leucovorin
  • oxaliplatin and capecitabine

Targeted therapy

Targeted therapy drugs may be used to treat stage 2 adenocarcinoma tumours at the gastroesophageal (GE) junction. They are usually combined with chemotherapy.

Trastuzumab is used with chemotherapy drugs to treat HER2-positive tumours. The most common combinations are:

  • trastuzumab, cisplatin and fluorouracil
  • trastuzumab, cisplatin and capecitabine

Immunotherapy

Nivolumab (Opdivo) is an immunotherapy drug that may be offered for stage 2 esophageal cancer. It may be given to people who still have cancer remaining after neoadjuvant therapy with chemoradiation and surgery to completely remove the tumour.

Surgery

Esophagectomy is surgery to remove all or part of the esophagus and lymph nodes around it. Part of the stomach may be removed as well. Before you are offered surgery, your healthcare team will do tests to make sure that you are healthy enough to have it done.

Esophagectomy is the type of surgery offered for stage 2 esophageal cancer when the person is healthy enough to have surgery. You may be offered surgery by itself or after chemoradiation.

Radiation therapy

External radiation therapy is the most common type of radiation therapy used to treat esophageal cancer.

Radiation therapy is combined with chemotherapy to treat stage 2 esophageal cancer. This is called chemoradiation. The 2 treatments are given during the same time period. Chemotherapy can make radiation therapy more effective in treating esophageal cancer.

Chemoradiation may be offered for stage 2 esophageal cancer:

  • before surgery (neoadjuvant therapy)
  • after surgery to reduce the risk that the cancer will come back (adjuvant therapy)

Clinical trials

Talk to your doctor about clinical trials open to people with esophageal cancer in Canada. Clinical trials look at new ways to prevent, find and treat cancer. Find out more about clinical trials.

Expert review and references

  • Abbas G, Krasna M. Overview of esophageal cancer. Annals of Cardiothoracic Surgery. 2017.
  • Saskatchewan Cancer Agency. Provincial Esophageal Cancer and Gastro-esophageal Junction Cancer Treatment Guidelines. Saskatchewan Cancer Agency; 2014.
  • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers (Version 2.2018). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
  • American Cancer Society. Treating Esophageal Cancer by Stage. 2017.
  • National Cancer Institute. Esophageal Cancer Treatment (PDQ®) Health Professional Version. 2018.
  • National Cancer Institute. Esophageal Cancer Treatment (PDQ®) Patient Version. 2018.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2024 Canadian Cancer Society